The EMA's CHMP is recommending updates to Summary of Product Characteristics (SmPC) of agomelatine [Thymanax, Valdoxan]

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1421, 2012-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety updates from EMA's CHMP

By  

Reactions Weekly, Vol. 1, Iss. 1360, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

The EMA's Pharmacovigilance Working Party (PhVWP) is recommending an update to the product labelling for rosuvastatin

By  

Reactions Weekly, Vol. 1, Iss. 1385, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

CHMP safety updates for Avastin and Thelin

By  

Reactions Weekly, Vol. 1, Iss. 1300, 2010-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

The EMA's Pharmacovigilance Working Party (PhVWP) has recommended updates to the product labelling of atomoxetine

By  

Reactions Weekly, Vol. 1, Iss. 1384, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Refusal of the marketing authorisation for Sumatriptan Galpharm has been confirmed by the EMA's CHMP.

By  

Reactions Weekly, Vol. 1, Iss. 1380, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite